Being able to test newly synthesized molecules is a pivotal part of early-stage drug discovery, with the data from assays driving decisions on the next molecules to be developed. The WAVEsystem, a Creoptix technology, with waveRAPID technology enables testing of full kinetic parameters for up to 400 compound fragments unattended in a 24-hour period.
Trevor Askwith presents how Domainex is using waveRAPID to accelerate the analog expansion to support our fragment and virtual screening hit ID platforms.